(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. eu. int http: // www. emea. eu. int EMEA 2006 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Jaká rizika jsou spojena s přípravkem EMSELEX?
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. eu. int http: / /www. emea. eu. int  EMEA 2006 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged EMSELEX presentaron 10,6 (68%) o 12,5 (77%) episodios menos de incontinencia a la semana, respectivamente, mientras que los pacientes que recibieron placebo presentaron 7 ó 7,5 (54 ó 58%) episodios menos a la semana.